Physician profile
Eric Hemberg
NPI 1992738926
$8,000.23
in general payments reported to CMS, 2019-2025
49 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,172 · 2020: $2,337 · 2021: $371 · 2022: $354 · 2023: $497 · 2024: $153 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,432.63 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $824.67 | 2019-2022 | |
| Novo Nordisk INC | $696.87 | 2019-2021 | |
| Pfizer INC. | $673.65 | 2019-2020 | |
| Amarin Pharma, INC. | $419.87 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $419.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.66 | 2019-2025 | Ofev |
| Janssen Pharmaceuticals, INC | $293.33 | 2019-2022 | |
| Astellas Pharma US INC | $259.60 | 2019-2020 | |
| Allergan, INC. | $245.87 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $214.11 | 2019-2020 | |
| Esperion Therapeutics, INC. | $148.85 | 2020 | |
| Sunovion Pharmaceuticals INC. | $141.93 | 2019 | |
| Lilly USA, LLC | $136.12 | 2019-2023 | Taltz |
| Inspire Medical Systems, INC. | $135.04 | 2023 | Inspire |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hemberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.